Renal Cell Carcinoma (RCC) Epidemiology Analysis and Forecast to 2033

Renal cell carcinoma (RCC) (International Classification of Diseases, 10th Revision [ICD-10] code C64) is a cancer that originates from the renal epithelium and accounts for 90% of kidney cancer cases. RCC accounts for the most cancer-related deaths; it is divided into more than 10 histologically distinct subtypes, but the most common is clear cell renal cell carcinoma (ccRCC) (Hsieh et al., 2017). Patients are evaluated on their individual characteristics, risk factors, and the extent of disease before the neoplasm is surgically resected and ablated; alternatively, samples can be biopsied and immunohistochemically strained to determine a systemic therapy plan (Padala et al., 2020). Localized RCC that is diagnosed in its early stages of disease can be effectively treated with surgery, but patients with metastatic disease have poorer outcomes. The five-year survival rate of patients with metastatic RCC is approximately 12% (NIH, 2024; Padala et al., 2020). In the late stages of the disease, the cancer may have spread to and beyond the lymph nodes and other distant organs of the body (Cancer Research UK, 2024c).

Scope

This report provides an overview of the risk factors and comorbidities, and the global and historical epidemiological trends for RCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of RCC and the five-year diagnosed prevalent cases of RCC. The diagnosed incident cases of RCC are segmented by age (18 years and older) and sex (men and women).
The diagnosed incident cases of RCC among men and women are segmented by stage at diagnosis (stage I, stage II, stage III, and stage IV), by International mRCC Database Consortium Prognostic Model (IMDC) risk group (favorable, intermediate, and poor risk), by stage IV non-clear cell RCC (nccRCC) patients, by RCC subtype (papillary RCC [pRCC] and chromophobe RCC [chRCC]), and by gene mutations (VHL, BAP1, SETD2, and ARID1A). The five-year diagnosed prevalent cases of RCC are also included in the report. This epidemiology forecast for RCC is supported by data obtained from country-specific oncology databases, peer-reviewed articles, and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of RCC across these markets.

Reasons to Buy

The Renal Cell Carcinoma epidemiology series will allow you to :

Develop business strategies by understanding the trends shaping and driving the global Renal Cell Carcinoma market.
Quantify patient populations in the global Renal Cell Carcinoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Renal Cell Carcinoma therapeutics in each of the markets covered.
Understand magnitude of the Renal Cell Carcinoma population by age, sex, stage at diagnosis, subtypes, and genetic mutations.

1 Renal Cell Carcinoma (RCC): Executive Summary

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology.
2.4.1 Sources
2.4.2 Forecast assumptions and methods.
2.4.3 Forecast assumption and methods: diagnosed incident cases of RCC
2.4.4 Forecast assumptions and methods: diagnosed incident cases of RCC by stage at diagnosis.
2.4.5 Forecast assumptions and methods: diagnosed incident cases of stage IV ccRCC by risk group.
2.4.6 Forecast assumptions and methods: diagnosed incident cases of stage IV nccRCC.
2.4.7 Forecast assumptions and methods: diagnosed incident cases of RCC by subtypes, papillary and chromophobe RCC.
2.4.8 Forecast assumptions and methods: diagnosed incident cases of RCC with VHL mutation by RCC subtype.
2.4.9 Forecast assumptions and methods: diagnosed incident cases RCC by BAP1 gene mutation.
2.4.10 Forecast assumptions and methods: diagnosed incident cases RCC by SETD2 gene mutation.
2.4.11 Forecast assumptions and methods: diagnosed incident cases RCC by ARID1A gene mutation.
2.5 Epidemiological forecast for RCC (2023-33)
2.5.1 Diagnosed incident cases of RCC.
2.5.2 Age-specific diagnosed incident cases of RCC
2.5.3 Sex-specific diagnosed incident cases of RCC
2.5.4 Diagnosed incident cases of RCC by stage at diagnosis.
2.5.5 Diagnosed incident cases of RCC by risk group.
2.5.6 Diagnosed incident cases of stage IV nccRCC.
2.5.7 Diagnosed incident cases of RCC by subtype - papillary and chromophobe RCC.
2.5.8 Diagnosed incident cases of RCC with VHL gene mutation by RCC subtype.
2.5.9 Diagnosed incident cases of RCC with genetic mutations BAP1, SETD2, and ARID1A
2.5.10 Five-year diagnosed prevalent cases of RCC
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact.
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Vice President of Disease Intelligence and Epidemiology
3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence

Contact the Publisher

List of Tables

Table 1: Summary of added data types
Table 2: Summary of updated data types
Table 3: Risk factors and comorbidities for RCC

List of Figures

Figure 1: 8MM, diagnosed incident cases of RCC, N, both sexes, ages =18 years, 2023 and 2033
Figure 2: 8MM, five-year diagnosed prevalent cases of RCC, N, both sexes, ages =18 years, 2023 and 2033
Figure 3: 8MM, diagnosed incidence of RCC, men and women, cases per 100,000 population, N, ages =18 years, 2013-33
Figure 4: 8MM, sources used to forecast the diagnosed incident cases of RCC
Figure 5: 8MM, sources used to forecast the diagnosed incident cases of RCC by stage at diagnosis
Figure 6: 8MM, sources used to forecast the diagnosed incident cases of stage IV nccRCC
Figure 7: 8MM, sources used and not used to forecast the diagnosed incident cases of stage IV ccRCC by risk group
Figure 8: 8MM, sources used and not used to forecast the diagnosed incident cases of RCC by subtypes papillary RCC and chromophobe RCC
Figure 9: 8MM, sources used and not used to forecast the diagnosed incident cases of RCC patients with VHL mutations
Figure 10: 8MM, sources used to forecast the diagnosed incident cases of RCC patients with a BAP1, SETD2, or ARID1A gene mutation
Figure 11: 8MM, diagnosed incident cases of RCC, N, both sexes, ages =18 years, 2023
Figure 12: 8MM, age-specific diagnosed incident cases of RCC by age, N, both sexes, 2023
Figure 13: 8MM, sex-specific diagnosed incident cases of RCC by sex, N, ages =18 years, 2023
Figure 14: 8MM, diagnosed incident cases of RCC by stage at diagnosis, N, both sexes, ages =18 years, 2023
Figure 15: 8MM, diagnosed incident cases of RCC by risk group, N, both sexes, ages =18 years, 2023
Figure 16: 8MM, diagnosed incident cases of stage IV nccRCC, N, both sexes, ages =18 years, 2023
Figure 17: 8MM, diagnosed incident cases of RCC by subtype - papillary and chromophobe RCC, N, both sexes, ages =18 years, 2023
Figure 18: 8MM, diagnosed incident cases of RCC with VHL gene mutation by RCC subtype, N, both sexes, ages =18 years, 2023
Figure 19: 8MM, diagnosed incident cases of RCC with genetic mutations BAP1, SETD2, and ARID1A, N, both sexes, ages =18 years, 2023
Figure 20: 8MM, five-year diagnosed prevalent cases of RCC, N, both sexes, ages =18 years, 2023

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3856EUR$3,995USD£3,201GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7712EUR$7,990USD£6,402GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€11568EUR$11,985USD£9,603GBP

Scope

Reasons to Buy

The Renal Cell Carcinoma epidemiology series will allow you to :

Table of Contents

Related Topics

Related Reports

Renal Cell Carcinoma Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Renal Cell Carcinoma Market Report and Forecast 2024-2032

Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2034

Advanced Renal Cell Carcinoma (RCC) - Market Insight, Epidemiology and Market Forecast - 2034

Kidney Cancer Therapeutics and Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2021 - 2029